Now results from its phase 3 Apollo trial show patisiran, which is co-developed with Sanofi, reduced nerve pain in the rare inherited disease familial amyloid polyneuropathy (FAP). If approved ...
Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, data from a global open-label extension (OLE ...
Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen. Both drugs target hereditary ATTR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback